drug

Pediococcus acidilactici, pA1c®HI postbiotic supplementation taking participants

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
DIETARY_SUPPLEMENT
Pre-approval / investigational in the US
Developed by Manuel Jesús Cuesta Zurita
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
DIETARY_SUPPLEMENT

Indications

Trials

1
Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.
NCT07371325—Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Manuel Jesús Cuesta Zurita
company
trial
Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.
NA
trial
indication
Schizophrenia
indication
Postbiotic Supplement
indication
SCHIZOPHRENIA 1 (Disorder)
indication
Metabolic Abnormalities
indication